India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
BUZZ-India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports Updates
** Nifty Pharma Index .NIPHARM down 1.52%
** Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
** Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
** "The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
** PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
** Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka